97 results about "MMP9" patented technology

This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

The present invention is directed to methods and kits based, at least in part, on the identification of allele-specific responsiveness or non-responsiveness to glatiramer acetate for the treatment of immune disorders, such as relapsing-remitting multiple sclerosis. The allele-specific responsiveness or non-responsiveness is based on polymorphisms in the following genes, CTSS, MBP, TCRB, CD95, CD86, IL-1R1, CD80, SCYA5, MMP9, MOG, SPP1 and IL-12RB2.

The invention discloses a method of identifying a gene associated with stage III primary cancer or lymph node metastasis. The genes so identified include CAV1, CST3, LIMK1, MMP2, MMP15, VEGF, ETV4, MMP9, PIK3C2B, and SERPIN1. Also disclosed are methods for diagnosis, prognosis, and treatment of cancer. The invention further discloses compositions for preventing and treating diseases.

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

Biomarkers, biomarker panels and methods for diagnosing osteoarthritis (OA) are disclosed, using measurement of the expression level of certain polypeptides in a test sample from a subject, including MCP1, IL8, KC, MMP2, MMP3, IL6, MMP1, RANTES, MMP9, IL1B, Apolipoprotein A1, Apolipoprotein E, DCN, CILP and COMP. Related methods for monitoring OA treatment efficacy, diagnostic reagents, and kits are also described.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C-C motif chemokine 1, C-C motif chemokine 17, C-C motif chemokine 21, C-C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to a gene marker for diagnosis of human hepatocellular carcinoma (HCC), which is selected from the group consisting of IGF2, VEGF, MET, SUMO2, CDK4, MMP9, PLK1, AFP, Rb1, CYP3A4, LAP3, RIZ, DLC1, ITIH1, FetB, ALDOB, SULT2A1, ASS, HP, SERIND1, EI24, HGD, RODH, F2, SORD, and KNG. The HCC is diagnosed effectively and efficiently based on detecting the expression levels of the present gene marker from the liver tissue sample of an individual to be diagnosed.

The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being:

• • SPP1, and
  • at least one gene from among A2M and VIM, and
  • at least one gene from among IL8, CXCL10 and ENG, and
  • optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.

The invention relates to a detection system for detecting a human immune state and belongs to the technical field of gene detection. The detection system provided by the invention is used for detecting 20 genes, including IFI27, ISG15, IFI44L, RSAD2, HERC5, IFITM3, IFI44, IFIT3, EPSTI1, IFIT1, HP, ANXA3, ARG1, FCGR1B, S100A12, MMP9, IL18R1, TLR3, GYG1 AND FCGR1A in peripheral blood; the assessment for the human immune state can be realized in the manner of increasing or reducing the expression level of each gene; and the genes are utilized to guide accurate medical treatment, including disease accurate parting, prognosis, treatment tracking and therapeutic evaluation. The detection system has excellent clinic application values and wide application prospects.

The present invention provides a method for determining the presence of prostate cancer in a subject which method comprises determining the level of expression of one or more markers in a blood sample from the subject, wherein said one or more markers comprise at least one of E2F3, c-met, pRB, EZH2, e-cad, CAXII, CAIX, HIF-1α, Jagged, PIM-1, hepsin, RECK, Clusterin, MMP9, MTSP-1, MMP24, MMP15, IGFBP-2, IGFBP-3, E2F4, caveolin, EF-1A, Kallikrein 2, Kallikrein 3 and PSGR.

The invention relates to a gene detection kit for prognosing gastric cancer metastasis. The kit comprises a DNA library building kit, wherein the DNA library building kit comprises a high-risk gene probe and a low-risk gene probe; the high-risk gene probe comprises CDH1, CDH2, SNAIL, SLUG, MUC4, MUC6, PRSS3, USP6, MLH1, MSH2, MSH6, PMS2, TGFBR2, MMP2, MMP9, BRCA1, BRCA2, PALB2, ATM, ATR, MUTYH, EMSY, ERCC4, RAD51, PARP1 and XRCC1; the low-risk gene probe comprises ATRX, BRIP1, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FANCO, FANCP, MDM2, MDM4, MLH1, NPM1, PP2R1A, PRKDC, RAD50, STAG2, XRCC5 and CRCC6. The invention further discloses a use method of the kit. The use method comprises the following steps: extracting cfDNA in a blood sample; building a library for the cfDNA through the DNA library building kit, and then sequencing the DNA to obtain a gene overall length sequence; carrying out gene mutation analysis on the gene overall length sequence.

The present invention concerns methods and compositions for treatment and determination of the presence or likelihood of an individual to have an ocular surface inflammation. In specific embodiments, a sample from the individual is assayed for the expression level of three or more genes, including IL-6, MMP3, MMP9, IFNy, SPRR-IA, HLA-DRA, MUC5AC, K7, and IL17A. Treatment is provided to an individual with ocular surface inflammation based upon the gene analysis.

The present disclosure provides compositions and methods of use comprising a matrix metalloproteinase-9 (MMP9) binding protein, alone or in combination with one or more additional therapeutic agents for the treatment or prevention of diseases and conditions.

The invention provides a molecular marker for diagnosing or treating glioma and applications thereof. Experimental studies show that the expression of microRNA-588 in glioma is significantly up-regulated in hypoxia state than in normoxia state. In vitro experiments show that the miR-588 can inhibit the invasive migration of glioma cells and VM formation ability. In order to clarify the molecular mechanism, further experiments find that Robo1 is a direct and functional related target of the miR-588 in glioma. The knocking out of the Robo1 inhibits the expression of matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), thereby inhibiting invasive migration of glioma and VM formation ability. Therefore, the miR-588 and the Robo1 can be used as a molecular marker for diagnosing or treating glioma.

This document provides prophylactic methods for reducing cancer metastasis by targeting LCN2, MMP9, and CX-CR4.

The invention discloses a kit for screening colorectal cancer hereditary susceptibility genes. The kit comprises colorectal cancer susceptibility gene specificity primers for amplifying a plurality of target regions in a to-be-detected sample, wherein the colorectal cancer susceptibility genes include at least one of rs10795668, MMP2, SMAD7, ADH2, ALDH2, CYP1A2, MMP-1, MTHFR, TP53, VEGF, COX-2, DNMT3B, hMLH1, LOC727677, MMP9, MTRR and TGF-beta 1. The kit can detect a plurality of regions of the colorectal cancer susceptibility genes at the same time, detecting efficiency is improved, detecting cost is reduced, and detecting accuracy and sensitivity are high.

The invention specifically relates to application of melittin in preparation of a drug used for inhibiting invasion metastasis of breast cancer cells, which belongs to the field of bioengineering technology. CD147 and MMP9 proteins exert significant effects on invasion and metastasis of breast cancer MCF-7 cells. The invention aims to find a CD147 expression inhibitor which is capable of hindering or reducing secretion of MMP9 and inhibiting invasion metastasis of cancer cells to cancerous peripheral tissue. According to the invention, MCF-7 cells are cultured at first, then different doses of melittin is used, and flow cytometry, ELISA and RT-PCR experimental results prove that expression of CD147 and MMP9 is suppressed in the MCF-7 cells treated by melittin; and then Transwell invasion chamber experiments are conducted to detect the migration rate of the MCF-7 cells treated by melittin. Melittin can inhibit invasion metastasis of the MCF-7 cells. Thus, a novel anti-breast cancer drug can be developed from melittin.

The invention relates to an application of a matrix metallo-proteinase inhibitor in resisting nuclear radiation, and specifically, the invention relates to biological susceptibility gene mmp9 of nuclear radiation, and further relates to a function for preventing nuclear radiation of a matrix metallo-proteinase inhibitor. The matrix metallo-proteinase inhibitor can be developed into dosage forms including subcutaneous injection, intramuscular injection and intravenous injection, and can be prepared into dosage forms including buccal tablets, nasal sprays, rectum administration agents with transmembrane carriers including transduction peptide and nanometer for prevention and treatment of nuclear radiation, and in addition, the matrix metallo-proteinase inhibitor also can be used for treatment on diseases including tumour.

A composition for preventing and/or treating piles contains at least one NO synthetase (NOS) inhibitor, especially iNOS inhibitor, at least one vascular angiogenesis inhibitor, especially VEGF inhibitor, and at least one matrix metal proteinase (MMP) inhibitor, especially MMP1, MMP3, MMP9 and/or MMP12 inhibitor.

Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, Arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated MMP production by alveolar macrophages. MMP9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by Arhgef1. Expression of ARHGEF1 by human peripheral blood monocytes varies between individuals and inversely correlates with fibronectin-mediated MMP9 production. Arhgef1 levels can function as a predictor for a pulmonary disease candidate and a thromboxane receptor antagonist can treat a pulmonary disease condition resulting from low Arhgef1 levels.

The invention provides methods and compositions for distinguishing ovarian cancer from a benign pelvic mass using two or more of the following biomarkers: IL-6, MMP9, tPA, IGFBP2, MMP7, Tenascin, NAP2, glycodelin, MCSF, MMP2, Inhibin A, uPAR, and EGFR. The methods are useful in distinguishing a benign pelvic mass from ovarian cancer in subjects, particularly in subjects identified as having increased CA125 levels.